She is an expert in rare disease and precision oncology, and focuses on disruptive technology adoption and companion diagnostic/therapeutic co-development strategies with an eye toward value-based care. Most recently, she was an advisor at Red Sky Partners LLC and the founder and managing director of Accendo. At Red Sky Partners, Alice advised high-growth life sciences and health tech companies on go-to-market and product value strategies. In 2018, she founded Accendo to accelerate entrepreneurial consumer-facing approaches to patient access and affordability of quality care.

She held prior strategy and operational leadership roles at Radius Health, AstraZeneca, and Sanofi Genzyme, where she launched multiple US and global specialty products and championed orphan drug and health equity initiatives across the globe. Her public sector experience spans innovation, trade, and healthcare policy through roles in the UK Government and US Office of Management and Budget.

Alice holds a Master of Public Policy from Harvard University and a Bachelor of Science in Biology from MIT. She serves on the Boards of Massachusetts Biotechnology Council, MassEcon, and PhagePro Inc. Additionally, she is a faculty member at Harvard-MIT HST Sloan Healthcare Ventures, a role she will retain during her tenure with the American Cancer Society.

In addition to her industry experience, Alice is a longtime American Cancer Society and American Cancer Society Cancer Action Network volunteer leader